docetaxel anhydrous has been researched along with Ventricular Dysfunction, Left in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amadori, D; Baselga, J; Benyunes, MC; Clark, E; Cortés, J; Ewer, MS; Knott, A; Miles, D; Ross, G; Swain, SM | 1 |
| Abbate, A; Biondi-Zoccai, G; Cavarretta, E; De Marco, E; Di Persio, S; Frati, G; Loperfido, F; Lotrionte, M; Mezzaroma, E; Palazzoni, G | 1 |
| Baselga, J; Benyunes, MC; Clark, E; Cortés, J; Hegg, R; Im, SA; Im, YH; Kim, SB; Knott, A; Pedrini, JL; Pienkowski, T; Roman, L; Ross, G; Swain, SM | 1 |
| Azli, N; Campos, D; Chan, S; Falkson, C; Kennedy, I; Krzakowski, M; Leonard, R; Martin, M; Murawsky, M; Nabholtz, JM; Pienkowski, T; Pinter, T; Pouillart, P; Riva, A; Szanto, J; Vorobiof, D; Zaluski, J | 1 |
| Hamazoe, R; Komuro, I; Murata, Y; Shimoyama, M; Sumi, KI | 1 |
3 trial(s) available for docetaxel anhydrous and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab; Ventricular Dysfunction, Left | 2013 |
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Ventricular Dysfunction, Left; Young Adult | 2012 |
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Health Status; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
2 other study(ies) available for docetaxel anhydrous and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Temporal changes in standard and tissue Doppler imaging echocardiographic parameters after anthracycline chemotherapy in women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Echocardiography, Doppler; Female; Fluorouracil; Heart Diseases; Humans; Middle Aged; Prospective Studies; Stroke Volume; Taxoids; Time Factors; Ventricular Dysfunction, Left | 2013 |
Docetaxel induced cardiotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Ventricular Dysfunction, Left | 2001 |